Fund+
People
- Board members
- Our team
Investment Strategy
Portfolio
- Current
- Exits
Your Project
News
Contact us

Press Release

Immunic Press Release

2021-10-15

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

NEW YORK, Oct. 14, 2021…

Coave Press Release

2021-10-12

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Coave Therapeutics appoints Olivier Danos…

Immunic Press Release

2021-10-01

Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

NEW YORK, Sept. 30, 2021…

Immunic Press Release

2021-09-22

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Immunic and the University Medical…

Horama Press Release

2021-09-16

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Coave Therapeutics and Théa Open…

Exevir Press Release

2021-09-01

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

ExeVir Announces First Patient Enrolled…

Cardior Press Release

2021-08-25

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Cardior Raises €64 M Series…

Exevir Press Release

2021-08-18

ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody

ExeVir announces first subjects dosed…

Horama Press Release

2021-07-22

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Coave Therapeutics Closes €33 million…

Immunic Press Release

2021-07-20

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Immunic, Inc. Announces Closing of…

1
…
6
7
8
9
10
…
17

Contact us

Address:
Groot Begijnhof 60
3000 Leuven
Belgium
Phone: +32 (0)16 90 50 00
Email: info@fundplus.be

Recent Articles

Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study
Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer
Novadip secures €10.4 million financing to complete pivotal Phase 3 trial

© 2019 FUND⁺- ALL RIGHTS RESERVED. |

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT Read More

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT